Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Antigen-presenting cell receptors, primarily the low-affinity Fc gamma receptors (FcγRII/CD32 and FcγRIII/CD16), are the key molecules responsible for the uptake and processing of Human Papillomavirus (HPV) L1 virus-like particles (VLPs) by dendritic cells and macrophages. These receptors facilitate the internalization of VLPs from high-risk HPV types, such as HPV16, 18, 33, and 58, which are the primary antigens in prophylactic HPV vaccines like Gardasil 9. A distinctive feature of HPV VLPs is their ability to bind directly to these receptors on immature antigen-presenting cells (APCs) even in the absence of specific antibodies, an interaction that serves as an intrinsic adjuvant by inducing APC maturation. This process involves the upregulation of co-stimulatory molecules and the secretion of pro-inflammatory cytokines, which are essential for the subsequent activation of T cells and the generation of a robust, long-lasting humoral immune response. Consequently, these receptors are fundamental to the high efficacy of current HPV vaccines in preventing cervical cancer and other HPV-associated malignancies. Beyond Fc gamma receptors, other molecules such as heparan sulfate proteoglycans and C-type lectin receptors (e.g., DC-SIGN) may also contribute to the initial attachment and uptake of VLPs. Understanding the precise interaction between VLPs and these receptors is vital for the development of next-generation vaccines with broader coverage or improved delivery methods.
Binding of HPV L1 virus-like particles (VLPs) to Fc gamma receptors (FcγRII and FcγRIII) on antigen-presenting cells (APCs) triggers their internalization and processing, leading to APC maturation and the presentation of viral antigens to T cells, which initiates a robust adaptive immune response.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Low-affinity Fc gamma receptor (FcγRII and FcγRIII) (FcγR).